| Document |
Document Title |
|
WO/2024/086790A1 |
The present disclosure provides 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine compounds of formula (I), which are therapeutically useful as USP1 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or...
|
|
WO/2024/086569A1 |
N-Biarylmethylene substituted pyrrolopyridinone, pyrrolopyrazinone, pyrrolopyrimidinone, and isoindolin-1-one compounds having a primary or secondary alcohol-containing group substituted on the biarylmethylene are positive allosteric mod...
|
|
WO/2024/083120A1 |
Disclosed in the present invention are a benzylaminoquinoline compound and a preparation method therefor. The present invention specifically relates to a compound represented by formula (II), a stereoisomer thereof and a pharmaceutically...
|
|
WO/2024/054785A3 |
Provided herein is a method for determining selectively increasing the expression levels of SSTR5 in pituitary tumor cells in a patient, the method comprising administering to the patient a glucocorticoid receptor modulator (GRM) to the ...
|
|
WO/2024/082654A1 |
Compounds having poly ADP-ribose polymerase inhibitory activity, pharmaceutical compositions thereof, and uses thereof are disclosed. In particular, the present invention relates to compounds of formula (I), pharmaceutical compositions c...
|
|
WO/2024/083086A1 |
A bicyclic αvβ1, αvβ6 and αvβ8 integrin inhibitor compound represented by formula (I), and a racemate, stereoisomer, tautomer, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, and a pharma...
|
|
WO/2024/083257A1 |
Provided in the present invention are an SOS1 protein degradation agent and a use thereof. Specifically, provided in the present invention is a formula (I) for a S-L-E compound, and a stereoisomer, enantiomer, diastereomer, deuterated co...
|
|
WO/2024/083256A1 |
Provided in the present invention are a pan-KRAS degrading agent, and a preparation method therefor and the use thereof. Specifically, disclosed in the present invention are a small molecule compound for targeted degradation of the pan-K...
|
|
WO/2024/086194A1 |
The present disclosure describes methods of treating a subject suffering from cancer using a combination therapy comprising (i) administering to the subject a therapeutically-effective amount of a compound that blocks SUMOylation in the ...
|
|
WO/2024/059212A3 |
Negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatr...
|
|
WO/2024/084217A1 |
The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein R1, B1, B2, B3, B4, B5, and...
|
|
WO/2024/086296A1 |
The present disclosure relates to the field of medicinal chemistry. In particular, the disclosure relates to a new class of small-molecules having a quinazoline structure or a quinoline structure according to Formula (I), wherein Ring A,...
|
|
WO/2024/086570A1 |
N-Biarylmethylene substituted pyrrolopyridinone, pyrrolopyrazinone, pyrrolopyrimidinone, and isoindolin-1-one compounds having a tertiary alcohol-containing group substituted on the biarylmethylene are positive allosteric modulators of t...
|
|
WO/2024/086809A1 |
This disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that restore p53 function. These compounds are useful, e.g., for treating a disease in which decreased p53 function contributes to the path...
|
|
WO/2024/085699A1 |
The present disclosure provides a compound of a specific chemical structure, an optical isomer, stereoisomer, isotopic variant, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof, which has excellent activity in te...
|
|
WO/2024/084450A1 |
The present disclosure provides bicyclic heteroaryl compounds and their derivatives of formula (I), which are therapeutically useful as PKMYT1 inhibitors. (I) These compounds are useful in the treatment and/or prevention of diseases or c...
|
|
WO/2024/083773A1 |
The present invention relates to compounds, compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythemato...
|
|
WO/2024/086061A2 |
Disclosed herein are compounds of formulae (I), (II), and (III) and a pharmaceutically acceptable salts thereof. Also disclosed herein are uses of compounds of formulae (I), (II), and (III), as well as pharmaceutically acceptable salts t...
|
|
WO/2024/086730A1 |
The application relates to heterocyclic compounds of the general formula (A) which act as inhibitors of the E3 ubiquitin-protein ligase Cbl-b useful for the treatment of cancer.
|
|
WO/2024/083204A1 |
The present invention relates to a salt and a crystal form of a heterocyclic derivative inhibitor, and a preparation method therefor and the use thereof. Particularly, the present invention relates to a salt and a crystal form of the com...
|
|
WO/2024/083111A1 |
The present invention relates to novel heterocyclic compounds, which are compounds having FGFR2 protein activity. Specifically, the present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates, po...
|
|
WO/2024/083201A1 |
The present invention belongs to the technical field of chemical medicines. Disclosed are a fused heterocyclic compound and the use thereof. The fused heterocyclic compound as represented by formula (II) provided in the present invention...
|
|
WO/2024/084364A1 |
The invention relates to 4-((6-(2,2-Difluoroethyl)-8-(2-hydroxy-2-methylcyclopentyl)-
7-oxo-7, 8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)piperidine-1-sulf
onamide or pharmaceutically acceptable salts thereof, to compositions containing ...
|
|
WO/2024/084390A1 |
Described herein are compounds of Formula I, wherein the variables are defined herein, their use as activators from AMPK, pharmaceutical compositions containing such compounds and their use to treat, for example, heart failure or periphe...
|
|
WO/2024/059216A3 |
Negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatr...
|
|
WO/2024/086682A2 |
5-HT2A receptor ligands and receptor-ligand complexes are synthesized. These ligands, which may link two indole containing moieties through an amine, may be used in therapeutically effective amounts, to treat mood disorders and neurologi...
|
|
WO/2024/086111A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2024/083160A1 |
Provided are a crystal form and an amorphous substance of an indoline spiro compound represented by formula (1), and a preparation method therefor and the use thereof. The X-ray powder diffraction pattern of the crystal form comprises ch...
|
|
WO/2024/037667A3 |
Disclosed are a fused ring heterocyclic compound represented by the following formula I, an optical isomer, a deuterated substance, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the subs...
|
|
WO/2024/086273A1 |
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
|
|
WO/2024/083218A1 |
The present invention relates to the technical field of chemical medicines. Disclosed are a substituted tetrahydropyridine compound and a use thereof. The substituted tetrahydropyridine compound as represented by formula I provided by th...
|
|
WO/2024/083164A1 |
Provided are an anisole solvate of an indoline spiro compound represented by formula (1), and a crystal form thereof, a preparation method therefor and the use thereof. The X-ray powder diffraction pattern of the crystal form comprises c...
|
|
WO/2024/086804A1 |
This disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that restore p53 function. These compounds are useful, e.g., for treating a disease in which decreased p53 function contributes to the path...
|
|
WO/2024/083933A1 |
There are disclosed certain 2,4,6-trisubstituted 1,3,5-triazine compounds of Formula (I), (I) and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are modulator...
|
|
WO/2024/083211A1 |
Disclosed is a heterocyclic deuterated compound and a use thereof, relating to the technical field of chemical medicine. The heterocyclic deuterated compound represented by formula (I) provided by the present invention can be used as a P...
|
|
WO/2024/081939A2 |
The present disclosure provides compounds of Formulae T-A, I-B. II-A. II-B. lll-A, III-B, IV-A. IV-B, V-A, V-B, Vl-A, and VI-B. and compounds shown in Table 13, Table 13 A, and Table 14, and pharmaceutically acceptable salts, solvates, h...
|
|
WO/2024/081775A1 |
The present invention provides improved reaction schemes and novel reaction intermediates for the synthesis of molecules useful as O-GlcNAcase (OGA) inhibitors.
|
|
WO/2024/080330A1 |
The present invention provides a compound having an excellent control effect against harmful arthropods. A compound represented by formula (1) and an N oxide thereof have an excellent control effect against harmful arthropods. [In the fo...
|
|
WO/2024/078448A1 |
Provided are an HPK1 kinase inhibitor, a preparation method therefor and the use thereof. The kinase inhibitor can adjust (for example, inhibit) HPK1 kinase activity, and thus can be used for treating various HPK1-related diseases includ...
|
|
WO/2024/078579A1 |
The present invention relates to an indole phthalocyanine compound, a preparation method therefor, and a use thereof in tumor diagnosis imaging. Specifically, the present invention relates to a compound having a structure represented by ...
|
|
WO/2024/081927A1 |
Provided herein are methods of improving (e.g., increasing) the production of viral particles (e.g., AAV) in mammalian cells (e.g., HEK293 or HEK293T cells) using selective HDAC6 inhibitors (e.g., compounds of Formula I, Formula II, or F...
|
|
WO/2024/080788A1 |
The present invention relates to a novel tricycle derivative compound and uses thereof, more specifically to a novel tricycle derivative compound having inhibitory activity for methionine adenosyltransferase 2A (MAT2A) and uses thereof.
|
|
WO/2024/080354A1 |
The present invention provides a compound, or an N-oxide thereof, which has an excellent controlling effect with respect to harmful arthropods and which is represented by formula (I) (in the formula: Q denotes a group represented by form...
|
|
WO/2024/078581A1 |
The present application relates to novel PROTAC compounds, and tautomers, stereoisomers, or pharmaceutically acceptable salts thereof, which degrade and/or inhibit the level or activity of BCL-XL proteins. The present application also re...
|
|
WO/2024/081889A1 |
This disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα). These compounds are useful for treating a disease...
|
|
WO/2024/078628A1 |
Provided is a method for treating osteoporosis, and further provided is a drug for treating osteoporosis, comprising: a therapeutically effective amount of ONT-380 or a pharmaceutically acceptable salt thereof, or a combination of ONT-38...
|
|
WO/2024/074497A1 |
The present invention relates to a compound of formula (I) or pharmaceutically acceptable salt thereof. The present invention further relates to the compound of formula (I) of the present invention for use in therapy. The compound is par...
|
|
WO/2024/076670A2 |
The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not l...
|
|
WO/2024/077273A2 |
The present disclosure relates generally to small molecule inhibitors of Sterile Alpha and TIR Motif containing 1 (SARM1) protein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomer...
|
|
WO/2024/073802A1 |
A method for detection of a nerve agent in a sample, which method comprises (a) irradiating an optical sensing element, the optical sensing element comprising a fluorescent sensing compound provided on a substrate, and measuring the lumi...
|
